Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
- Caridad Pontes*
- , Corinne Zara
- , Josep Torrent-Farnell
- , Merce Obach
- , Cristina Nadal
- , Patricia Vella-Bonanno
- , Michael Ermisch
- , Steven Simoens
- , Renata Curi Hauegen
- , Jolanta Gulbinovic
- , Angela Timoney
- , Antony P. Martin
- , Tanja Mueller
- , Anna Nachtnebel
- , Stephen Campbell
- , Gisbert Selke
- , Tomasz Bochenek
- , Celia C. Rothe
- , Ileana Mardare
- , Marion Bennie
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
29
Citations
(Scopus)